Home » Newsletters » BioWorld Science

BioWorld Science

July 19, 2013

View Archived Issues

Novel plasmid-encoded treatment for patients with type 1 diabetes

Osthole-derived compound has beneficial effects on learning and memory

Preliminary data presented for the anti-protofibrillar Abeta MAb SAR-228810

Noscira presents results from the ARGO trial of tideglusib

Merck Serono presents new agents for autoimmune and inflammatory disorders

Pfizer reports novel GHR antagonist antibodies

Allergan discloses new prostanoid receptor antagonists

New PI3Kdelta inhibitors synthesized at Novartis

Chinese group patents new Raf kinase inhibitors for cancer

BeiGene synthesizes novel signal transduction pathway inhibitors

Bausch + Lomb acquires option to license dry eye syndrome drug

Ensemble Therapeutics and Alexion to discover macrocycle candidates for rare disorders

Santarus completes enrollment in CONTRIBUTE study

NIH awards phase I SBIR grant to Cureveda

Venaxis' pivotal trial of APPY1 Test passes first of two futility analyses

EMA committee recommends orphan drug status for Soliris in rare neurological disease

Alkermes describes new pain, multiple sclerosis and cancer immunotherapy candidates

FDA approves Janssen's Simponi Aria for treatment of moderately to severely active RA

Celgene to discontinue phase III trial in elderly patients with B-cell CLL

Mesoblast receives funds from Australian government for R&D activities

Cooperative phase IIb trial of MediciNova's MN-166 begins in patients with progressive MS

Phase III study of Spinal Restoration's Biostat System for low back pain misses primary endpoint

EMA grants orphan drug status to OXiGENE's Zybrestat in ovarian cancer

AstraZeneca expands cardiovascular disease pipeline with acquisition

Kyowa Hakko Kirin files application in Japan to expand indication for mogamulizumab

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...